Literature DB >> 17904842

Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position.

Kenneth G Holden1, Kevin Tidgewell, Alfred Marquam, Richard B Rothman, Hernán Navarro, Thomas E Prisinzano.   

Abstract

Modification of the C-1 ketone of salvinorin A (2a) produces analogues with opioid antagonist properties. Of particular significance is the finding that 1-deoxo-1,10-dehydrosalvinorin A (11a) is a moderately potent antagonist at all three opioid receptor subtypes, and that herkinorin (2b), a mu agonist, is converted to a weak antagonist by removal of the C-1 ketone (3b and 11b). These observations suggest that the ketone of 2b is a key structural feature responsible for mu agonist activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904842      PMCID: PMC2111044          DOI: 10.1016/j.bmcl.2007.09.050

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  25 in total

1.  Activation of G protein by opioid receptors: role of receptor number and G-protein concentration.

Authors:  A E Remmers; M J Clark; A Alt; F Medzihradsky; J H Woods; J R Traynor
Journal:  Eur J Pharmacol       Date:  2000-05-19       Impact factor: 4.432

2.  ACTH: a short introductory review.

Authors:  R Schwyzer
Journal:  Ann N Y Acad Sci       Date:  1977-10-28       Impact factor: 5.691

Review 3.  Drug efficacy at G protein-coupled receptors.

Authors:  Terry Kenakin
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

Review 4.  Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists.

Authors:  P S Portoghese
Journal:  Trends Pharmacol Sci       Date:  1989-06       Impact factor: 14.819

Review 5.  Pharmacology of opioid and nonopioid analgesics in chronic pain states.

Authors:  T J Martin; J C Eisenach
Journal:  J Pharmacol Exp Ther       Date:  2001-12       Impact factor: 4.030

6.  Heterogeneous ligand-mediated Ca(++) responses at wt and mutant alpha(2A)-adrenoceptors suggest multiple ligand activation binding sites at the alpha(2A)-adrenoceptor.

Authors:  P J Pauwels; F C Colpaert
Journal:  Neuropharmacology       Date:  2000-08-23       Impact factor: 5.250

7.  Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells.

Authors:  L Gazi; I Bobirnac; M Danzeisen; E Schüpbach; D Langenegger; B Sommer; D Hoyer; M Tricklebank; P Schoeffter
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

8.  Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.

Authors:  J R Traynor; S R Nahorski
Journal:  Mol Pharmacol       Date:  1995-04       Impact factor: 4.436

9.  Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.

Authors:  Bryan L Roth; Karen Baner; Richard Westkaemper; Daniel Siebert; Kenner C Rice; SeAnna Steinberg; Paul Ernsberger; Richard B Rothman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

10.  Both ligand- and cell-specific parameters control ligand agonism in a kinetic model of g protein-coupled receptor signaling.

Authors:  Tamara L Kinzer-Ursem; Jennifer J Linderman
Journal:  PLoS Comput Biol       Date:  2007-01-12       Impact factor: 4.475

View more
  15 in total

1.  A theoretical biogenesis overview of diterpenes isolated from Salvia microphylla.

Authors:  J Alejandro Posada-Salgado; Elihú Bautista; Gabriel Cuevas; Karina Martinez-Mayorga
Journal:  J Mol Model       Date:  2015-11-10       Impact factor: 1.810

Review 2.  Ethnobotany as a pharmacological research tool and recent developments in CNS-active natural products from ethnobotanical sources.

Authors:  Will C McClatchey; Gail B Mahady; Bradley C Bennett; Laura Shiels; Valentina Savo
Journal:  Pharmacol Ther       Date:  2009-05-05       Impact factor: 12.310

Review 3.  Salvinorin A analogs as probes in opioid pharmacology.

Authors:  Thomas E Prisinzano; Richard B Rothman
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

4.  Modular Approach to pseudo-Neoclerodanes as Designer κ-Opioid Ligands.

Authors:  Alexander M Sherwood; Samuel E Williamson; Rachel S Crowley; Logan M Abbott; Victor W Day; Thomas E Prisinzano
Journal:  Org Lett       Date:  2017-09-14       Impact factor: 6.005

Review 5.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

Review 6.  A review of salvinorin analogs and their kappa-opioid receptor activity.

Authors:  Jeremy J Roach; Ryan A Shenvi
Journal:  Bioorg Med Chem Lett       Date:  2018-03-12       Impact factor: 2.823

7.  Semisynthetic neoclerodanes as kappa opioid receptor probes.

Authors:  Kimberly M Lovell; Tamara Vasiljevik; Juan J Araya; Anthony Lozama; Katherine M Prevatt-Smith; Victor W Day; Christina M Dersch; Richard B Rothman; Eduardo R Butelman; Mary Jeanne Kreek; Thomas E Prisinzano
Journal:  Bioorg Med Chem       Date:  2012-03-01       Impact factor: 3.641

8.  Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers.

Authors:  Thomas A Munro; Katharine K Duncan; Wei Xu; Yulin Wang; Lee-Yuan Liu-Chen; William A Carlezon; Bruce M Cohen; Cécile Béguin
Journal:  Bioorg Med Chem       Date:  2007-10-24       Impact factor: 3.641

9.  Synthesis of deacetyl-1,10-didehydrosalvinorin G.

Authors:  Zhongze Ma; David Y W Lee
Journal:  Tetrahedron Lett       Date:  2008-03-10       Impact factor: 2.415

10.  Metabolic changes in the rodent brain after acute administration of salvinorin A.

Authors:  Jacob M Hooker; Vinal Patel; Shiva Kothari; Wynne K Schiffer
Journal:  Mol Imaging Biol       Date:  2009-01-09       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.